tiprankstipranks
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics price target raised to $11 from $10 at Roth Capital
The FlyEntrada Therapeutics price target raised to $11 from $10 at Roth Capital
9d ago
TRDA
Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)
PremiumThe Fly
Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)
20d ago
TRDA
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
PremiumCompany Announcements
Entrada Therapeutics Stockholders Approve Directors and Equity Plans
3M ago
8K
TRDA
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
PremiumThe Fly
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
3M ago
TRDA
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
PremiumCompany Announcements
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
3M ago
8K
TRDA
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target lowered to $10 from $19 at Roth Capital
4M ago
NVS
TRDA
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
4M ago
TRDA
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
Premium
The Fly
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
4M ago
TRDA
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
PremiumRatings
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
4M ago
TRDA
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
PremiumThe Fly
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
4M ago
TRDA
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
PremiumCompany Announcements
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
4M ago
8K
TRDA
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
PremiumThe Fly
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
5M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe FlyEntrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
Premium
The Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
5M ago
TRDA
Entrada Therapeutics management to meet with Oppenheimer
Premium
The Fly
Entrada Therapeutics management to meet with Oppenheimer
5M ago
TRDA
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
PremiumRatings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
6M ago
TRDA
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
6M ago
TRDA
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
PremiumThe Fly
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
6M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
PremiumRatings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
6M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
PremiumRatingsEntrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
6M ago
TRDA
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
Premium
The Fly
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
6M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
7M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >